906652-17-3

Upstream product

• 906651-98-7 [(S,E)-1-((2R,3S,4R,5S,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)nonadec-4-en-3-yl]-bis carbamic acid tert-butyl ester 
• 906651-94-3 (R,E)-2-methyl-N-(3-((2R,3S,4R,5S,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)propylidene)propane-2-sulfinamide 
• 906652-11-7 (S,E)-1-((2R,3S,4R,5S,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)nonadec-4-en-3-amine 
• 906652-12-8 {(E)-(S)-1-[2-((2R,3S,4R,5S,6R)-3,4,5-Tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yl)-ethyl]-heptadec-2-enyl}-carbamic acid tert-butyl ester 
• 629-74-3 hexadec-1-yne 
• 53008-63-2 methyl 2,3,4,6-tetra-O-benzyl-α-D-galactopyranoside 
• 450370-39-5 3-((2R,3S,4R,5S,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)propanal 

Downstream Products

• 906652-19-5 Hexacosanoic acid {(1S,2R,3S)-2,3-dihydroxy-1-[2-((2R,3S,4R,5S,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yl)-ethyl]-heptadecyl}-amide 

Relevant academic research and scientific papers

NOVEL TH2 POLARIZING COMPOUNDS

The present invention relates to a pharmaceutical composition, particularly to a pharmaceutical composition for use in the treatment and/or prevention of immune-mediated diseases which are characterized by a Th1 environment such as autoimmune diseases, wh

Expedient synthesis of the α-C-glycoside analogue of the immunostimulant galactosylceramide (KRN7000)

Key reactions in a concise synthesis of an α-C-galactosylceramide analogue of KRN7000 include a diastereoselective alkenylalane addition to an N-tert-butanesulfinyl imine and the use of an epoxidation/carbamate ring opening sequence to install the aminodi